Small Molecule Drugs in Inflammatory Bowel Diseases

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and Ulcerative Colitis (UC), are chronic intestinal inflammatory conditions with complex etiologies.
• Current treatments like anti-TNF-alpha biologics have improved management but are insufficient for about one-third of patients due to non-response or intolerance.

Purpose of the Study:

• To review recently authorized and investigational orally administered Small Molecule Drugs (SMDs) for IBD treatment.
• To highlight novel pharmacological pathways being explored for CD and UC management.

Main Methods:

• Comprehensive literature review of authorized and phase II/III developmental SMDs for IBD.
• Analysis of pharmacological pathways including JAK inhibitors, sphingosine-1-phosphate receptor modulators, and phosphodiesterase 4 inhibitors.

Main Results:

• SMDs represent a new therapeutic class for IBD, offering oral administration and novel mechanisms of action.
• Several SMDs targeting pathways like JAK, S1P, and PDE4 are in advanced development for CD and UC.

Conclusions:

• Orally administered SMDs show promise in overcoming limitations of existing IBD therapies, such as anti-drug antibodies and parenteral administration issues.
• These novel agents are expected to expand treatment options for patients with moderate-to-severe CD and UC, particularly those with inadequate response to biologics.